canyon landscape

Infigratinib in Recurrent High-Grade Glioma Patients

This trial is an open-label, multicenter, Phase 0 trial that will enroll up to 20 participants with recurrent high-grade glioma with FGFR1 K656E or FGFR3 K650E mutation or FGFR3-TACC3 translocation which are scheduled for resection. In the lead-in cohort, a total of 20 participants will be enrolled into the proposed phase 0 clinical trial. Participants will be administered infigratinib prior to surgical resection of their tumor.

Open and enrolling subjects.
Phoenix, Arizona
Total Participants
Primary Sponsor
Nader Sanai
Additional Sponsor(s)
Ivy Brain Tumor Center
Barrow Neurological Institute
QED Therapeutics